Compare Stocks

→ Move Your Money Before May 1 (From Stansberry Research) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARCT Arcturus Therapeutics	$26.55 +1.5%	$33.94	$17.52 ▼ $43.81	$714.73M	2.6	452,463 shs	275,687 shs
CALA Calithera Biosciences	$0.02 -31.0%	$0.02	$0.01 ▼ $0.50	$97K	-0.17	1,535 shs	261 shs
CERC Cerecor	$14.98 +5.5%	$2.60	$1.98 ▼ $4.50	$1.44B	1.44	1.27 million shs	160,992 shs
CNCE Concert Pharmaceuticals	$8.37	$8.37	$2.66 ▼ $8.55	$401.26M	0.52	2.97 million shs	N/A
NWBO Northwest Biotherapeutics	$0.49 +1.7%	$0.53	$0.40 ▼ $1.09	$584.06M	-0.68	1.72 million shs	1.30 million shs

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARCT Arcturus Therapeutics	-3.00%	-0.57%	-18.55%	-17.50%	-1.80%
CALA Calithera Biosciences	-31.03%	-20.16%	0.00%	-33.33%	-52.61%
CERC Cerecor	+15.23%	+24.73%	+223.95%	+236.63%	+404.38%
CNCE Concert Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
NWBO Northwest Biotherapeutics	+3.67%	-6.47%	-10.17%	-20.10%	-3.64%

Protect Yourself While There’s Still Time … (Ad)

The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.

4 simple steps to protect your privacy and money before it’s too late.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARCT Arcturus Therapeutics	2.7649 of 5 stars	3.5	2.0	0.0	0.0	2.8	3.3	0.6
CALA Calithera Biosciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CERC Cerecor	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CNCE Concert Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NWBO Northwest Biotherapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARCT Arcturus Therapeutics	3.00	Buy	$61.33	131.01% Upside
CALA Calithera Biosciences	N/A	N/A	N/A	N/A
CERC Cerecor	N/A	N/A	N/A	N/A
CNCE Concert Pharmaceuticals	N/A	N/A	N/A	N/A
NWBO Northwest Biotherapeutics	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest ARCT, CERC, CNCE, CALA, and NWBO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/20/2024	ARCT Arcturus Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00
3/8/2024	ARCT Arcturus Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
2/8/2024	ARCT Arcturus Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$40.00 ➝ $48.00

(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARCT Arcturus Therapeutics	$169.93M	4.21	N/A	N/A	$10.42 per share	2.55
CALA Calithera Biosciences	$9.75M	0.01	N/A	N/A	($0.40) per share	-0.05
CERC Cerecor	$6.70M	214.66	N/A	N/A	$0.22 per share	68.09
CNCE Concert Pharmaceuticals	$32.58M	12.32	N/A	N/A	$3.24 per share	2.58
NWBO Northwest Biotherapeutics	$1.93M	302.62	N/A	N/A	($0.06) per share	-8.08

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARCT Arcturus Therapeutics	-$29.73M	-$1.04	N/A	10.06	N/A	-15.65%	-18.22%	-11.95%	5/8/2024 (Confirmed)
CALA Calithera Biosciences	-$39.65M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
CERC Cerecor	-$63.50M	-$0.57	N/A	N/A	N/A	-1,194.82%	-261.82%	-133.96%	N/A
CNCE Concert Pharmaceuticals	-$80.05M	-$3.21	N/A	N/A	N/A	N/A	-109.43%	-76.65%	N/A
NWBO Northwest Biotherapeutics	-$62.60M	-$0.06	N/A	∞	N/A	-3,240.11%	N/A	-207.51%	5/8/2024 (Estimated)

Latest ARCT, CERC, CNCE, CALA, and NWBO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2024	N/A	ARCT Arcturus Therapeutics	-$1.17	N/A	+$1.17	N/A	N/A	N/A
3/7/2024	Q4 2023	ARCT Arcturus Therapeutics	-$1.69	-$0.32	+$1.37	-$0.32	$64.14 million	$33.99 million
3/5/2024	Q4 2023	NWBO Northwest Biotherapeutics	N/A	-$0.02	-$0.02	-$0.02	N/A	$0.45 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARCT Arcturus Therapeutics	N/A	N/A	N/A	N/A	N/A
CALA Calithera Biosciences	N/A	N/A	N/A	N/A	N/A
CERC Cerecor	N/A	N/A	N/A	N/A	N/A
CNCE Concert Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NWBO Northwest Biotherapeutics	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARCT Arcturus Therapeutics	N/A	4.72	4.72
CALA Calithera Biosciences	N/A	N/A	N/A
CERC Cerecor	0.79	2.19	2.18
CNCE Concert Pharmaceuticals	N/A	9.03	9.03
NWBO Northwest Biotherapeutics	N/A	0.09	0.09

Ownership

Institutional Ownership

Company	Institutional Ownership
ARCT Arcturus Therapeutics	94.54%
CALA Calithera Biosciences	N/A
CERC Cerecor	62.84%
CNCE Concert Pharmaceuticals	70.63%
NWBO Northwest Biotherapeutics	0.04%

Insider Ownership

Company	Insider Ownership
ARCT Arcturus Therapeutics	13.80%
CALA Calithera Biosciences	6.60%
CERC Cerecor	45.70%
CNCE Concert Pharmaceuticals	11.33%
NWBO Northwest Biotherapeutics	9.40%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ARCT Arcturus Therapeutics	180	26.92 million	23.20 million	Optionable
CALA Calithera Biosciences	8	4.87 million	4.55 million	Not Optionable
CERC Cerecor	31	96.01 million	N/A	Not Optionable
CNCE Concert Pharmaceuticals	64	47.94 million	42.51 million	Optionable
NWBO Northwest Biotherapeutics	25	1.20 billion	1.09 billion	Not Optionable

ARCT, CERC, CNCE, CALA, and NWBO Headlines

Source	Headline
	Northwest Biotherapeutics (OTCMKTS:NWBO) Stock Price Crosses Below 200-Day Moving Average of $0.65 americanbankingnews.com - April 24 at 4:06 AM
	Northwest Biotherapeutics (OTCMKTS:NWBO) Stock Passes Below 200-Day Moving Average of $0.67 americanbankingnews.com - April 16 at 3:34 AM
	Northwest Biotherapeutics Appoints Seasoned Business Executive and Investor To Its Board of Directors prnewswire.com - March 21 at 11:09 AM
	‘Spoofing’ case might draw back curtain on high-speed trading firms ft.com - March 2 at 10:11 AM
	Northwest Biotherapeutics, Inc. (NWBO) uk.finance.yahoo.com - February 29 at 2:53 PM
	Northwest Biotherapeutics Stock (OTC:NWBO), Short Interest Report benzinga.com - February 23 at 12:07 AM
	Northwest Biotherapeutics Moves From Optimization of Flaskworks Prototype to Fabrication of GMP-Compliant Units For Installation, Validation and Final Testing Prior to Regulatory Certification finance.yahoo.com - February 7 at 4:37 PM
	Northwest Biotherapeutics submits marketing application to UK MHRA for DCVax-L msn.com - December 22 at 10:28 AM
	Northwest Biotherapeutics Announces That A Marketing Authorization Application Has Been Submitted To The UK MHRA For DCVax-L For Glioblastoma finanznachrichten.de - December 21 at 12:53 PM
	Northwest Biotherapeutics Announces That A Marketing Authorization Application Has Been Submitted To The UK MHRA For DCVax®-L For Glioblastoma finance.yahoo.com - December 21 at 12:53 PM
	Northwest Biotherapeutics Provides Update On Final Preparations For Marketing Authorization Application finance.yahoo.com - November 22 at 2:22 PM
	Northwest Biotherapeutics Inc NWBO morningstar.com - October 31 at 12:12 PM
	Northwest Bio: Another Small Filing Delay msn.com - October 14 at 10:44 AM
	NW Bio dips on announcing delay in submission of marketing application for DCVax seekingalpha.com - October 13 at 12:56 PM
	Northwest Biotherapeutics Shares Slide on Application Delay marketwatch.com - October 13 at 12:56 PM
	Northwest Biotherapeutics Provides Update On Near Term Plans For Submission of Marketing Authorization Application finance.yahoo.com - October 13 at 12:56 PM
	Police searching for suspects in Northwest DC shooting wjla.com - October 10 at 10:28 AM
	Northwest Biotherapeutics Announces That Dr. Linda Liau Has Joined The Company's Scientific Advisory Board finance.yahoo.com - September 12 at 6:48 PM
	Sports Betting In The Northwest Territories- Is it Legal? Best Sportsbooks In The NWT basketballinsiders.com - August 30 at 6:42 PM
	Northwest Bio: Is There Ever Going To Be A Right Time? msn.com - August 17 at 9:29 PM
	Northwest Missouri State University usnews.com - August 6 at 5:59 PM
	Northwest Hospital health.usnews.com - August 4 at 6:51 PM
	Standing Stone Circles: The most ancient builders of Northwest Arabia nationalgeographic.com - August 3 at 8:41 AM
	Siloam Springs News nwaonline.com - July 22 at 1:52 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Arcturus Therapeutics

NASDAQ:ARCT

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Calithera Biosciences

NASDAQ:CALA

Calithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.

Cerecor

NASDAQ:CERC

Cerecor, Inc. is a biopharmaceutical company, which engages in the development and commercialization of treatments for rare and orphan diseases. Its lead product candidates include CERC-801, CERC-802, and CERC-803, which are therapies for inherited metabolic disorders known as congenital disorders of glycosylation. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Rockville, MD.

Concert Pharmaceuticals

NASDAQ:CNCE

Concert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. Its product candidates target a range of diseases including autoimmune disorders, inflammation, and central nervous system disorders. The company was founded by Richard H. Aldrich, Roger D. Tung and Christoph H. Westphal on April 12, 2006 and is headquartered in Lexington, MA.

Northwest Biotherapeutics

OTCMKTS:NWBO

Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial